The month of April was a bit lighter in quantity of hires, but those we did see were high-profile: pharma and biotech saw at least four CEO changes, as well as numerous board chairs.
March wasn’t the busiest month for big pharma shakeups, especially compared to the start of the year, but there was plenty of hustle and bustle at smaller pharma and biotech firms.
February may be the shortest month, but for pharma hires and appointments it was a big one, with multiple high-level shake-ups at Sanofi, Johnson & Johnson, Bayer, and more.
Because of the holidays and the hustle and bustle around JP Morgan, we’re wrapping up our hires roundups from December and January into three double issues – stay tuned for other roundups f
Japan’s Taisho Pharmaceutical looks like it could be heading into private ownership, thanks to a management buyout offer (MBO) that could value the company at almost $5 bi
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio